The newest generation of GLP-1 drugs are being hailed by some as “miracle drugs” for the treatment of obesity. But GLP-1s are expensive, insurance coverage is limited, and not everyone with obesity can and or wants to take them. In this episode, which is based on Goldman Sachs Research’s latest Top of Mind report, obesity medicine physician Dr. Fatima Cody Stanford and Jonathan Gruber, professor of economics and chairman of the Economics Department at MIT, discuss how large the addressable market for GLP-1s actually is and the implications for US fiscal health.
If you want more insights from Goldman Sachs, make sure to visit GS.com and sign up for Briefings, a weekly newsletter from Goldman Sachs about trends spanning markets, industries, and the global economy.
Oil: Lower for Even Longer
Small Business in the Big Easy: Powering an Economic Revival
Brittle Markets: The Risks from Falling Liquidity
The Future of Finance
Global Equity Markets in Flux
The State of the Markets: Gary Cohn on Interest Rates, Liquidity and Risk Management
Mainframes and Back Again: Lessons from 25 Years in Technology
A Conversation with Lloyd Blankfein
Planes, Brains and Automobiles: The Future of Innovation
The UK Macro Environment
Revitalizing Communities Through Impact Investing
Artificial Intelligence: The Next Wave of Disruption
The Long-term Potential of the Growth Markets
The Future of the US-China Economic Relationship
The Global Growth Landscape
The New Oil Order
Macro Themes for Fixed Income Investors in 2015
A Revolution in Cancer Treatment
Create your
podcast in
minutes
It is Free
The emPOWERed Half Hour
TED Radio Hour
FT Alphachat
Freakonomics Radio
Odd Lots
Slate Money